RXRX241220C11000
- 0.05
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Trending Industry Today: Serve Robotics Leads Gains In NVIDIA Portfolio Stocks
Trending Industry Today: SoundHound AI Leads Gains Pre-Market In NVIDIA Portfolio Stocks
Trending Industry Today: Applied Digital Leads Gains In NVIDIA Portfolio Stocks
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Trending Industry Today: Serve Robotics Leads Gains Pre-Market In NVIDIA Portfolio Stocks
Recursion Pharmaceuticals Insider Sold Shares Worth $287,200, According to a Recent SEC Filing
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
Trending Industry Today: SoundHound AI Leads Losses In NVIDIA Portfolio Stocks
Cathie Wood's ARK Investment Buys 653K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc
Recursion Pharmaceuticals Analyst Ratings
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating
"Nvidia Magic" Strikes Again! Exploring Nvidia's Latest AI Investment Landscape
BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating